Ionis Pharmaceuticals(IONS) - 2025 Q1 - Earnings Call Presentation

Financial Performance & Guidance - Increased 2025 financial guidance by >20%[52] - 2025 revenue guidance is $725-$750 million, up from prior guidance of >$600 million[56] - Anticipated operating loss for 2025 is <$375 million, improved from prior guidance of <$495 million[56] - Cash and short-term investments stand at ~$1.9 billion[56] - Q1 2025 revenue was $132 million, including $76 million in commercial revenue and $56 million in R&D revenue[52] Product Launches & Pipeline - TRYNGOLZA generated over $6 million in net product sales in its first full quarter of launch[20,54] - TRYNGOLZA prescriptions are split ~60% commercial and ~40% government coverage[23] - Donidalorsen U.S approval PDUFA date is August 21, 2025[15] - Olezarsen sHTG Phase 3 (CORE and CORE2) data is expected in Q3 2025[15] - Median fasting baseline TG levels in CORE and CORE2 studies were 836 mg/dL and 749 mg/dL, respectively[40] - 84% of switch patients surveyed preferred Donidalorsen[46]